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Background. This paper presents unpublished clinical and economic data associated with open surgical repair (OSR) in low risk
(LR) patients and how it compares with EVAR and OSR in high risk (HR) patients with an AAA > 5.5cm. Design.D a t af r o m
a 1-year prospective observational study was used to compare EVAR in HR patients versus OSR in HR and LR patients. Results.
Between 2003 and 2005, 140 patients were treated with EVAR and 195 with OSR (HR: 52; LR: 143). The 1-year mortality rate with
EVAR was statistically lower than HR OSR patients and comparable to LR OSR patients. One-year health-related quality of life was
lower in the EVAR patients compared to OSR patients. EVAR was cost-eﬀective compared to OSR HR but not when compared to
OSR LR patients. Conclusions. Despite a similar clinical eﬀectiveness, these results suggest that, at the current price, EVAR is more
expensive than open repair for low risk patients.
1.Introduction
In 2002, the Ministry of Health and Long Term Care
(MOHLTC) of Ontario conducted a review of primary
studies on endovascular repair (EVAR) for abdominal
aortic aneurysms (AAA) as well as a review of previous
international and Canadian Health Technology Assessments
(HTA) [1]. Due to the informational uncertainty associated
with the long-term eﬀectiveness of EVAR, the MOHLTC
recommended that an Ontario-speciﬁc evaluation of the
technology was warranted. To evaluate EVAR, the MOHLTC
provided funding on a one-time basis to support a 24-
month EVAR evaluation at London Health Science Centre
(LHSC) Endovascular Program [1]. A condition of this
fundingwasthatLHSCwouldcollaboratewiththePrograms
for Assessment and Technology in Health (PATH) Research
Institute at St. Joseph’s Healthcare Hamilton to design and
conduct a “ﬁeld evaluation” to support the assessment
of the eﬀectiveness and cost-eﬀectiveness of EVAR com-
pared to open surgical repair (OSR) in Ontario. Following
the evidence generated by this study, the Ontario Health
Technology Advisory Committee (OHTAC) recommended
increased access to EVAR in high risk patients [2]. As a
result, EVAR was changed from an uninsured to insured
provincial service (i.e., a fee code introduced) and several
vascular programs in the province were restructured to
accommodate EVAR for high risk patients. This funding
decision was also consistent with the 2005 recommendations
of the Canadian Society for Vascular Surgery (CSVS): “EVAR
should be the procedure of choice for patients with suitable
vascular anatomy who are at intermediate or high risk (6%–
10%) for perioperative morbidity or death with open repair.2 International Journal of Vascular Medicine
For patients at low risk (2%–4%), open repair remains the
current standard ...”[ 3]. Following an updated review of
the evidence in 2010, OHTAC did not recommend the use
of EVAR in low risk patients [4].
In contrast, in the UK, the National Institute for Health
andClinicalExcellence(NICE)recentlyrecommendedEVAR
for all patients suitable for surgical intervention (i.e., OSR)
independently of their surgical risk [5, 6]. Although NICE
economic model supported that EVAR was not as cost
eﬀective in patients with a good “ﬁtness” (e.g., low surgical
risk), NICE estimated that it was not possible to exclude
a category of patients (e.g., low risk) due to the lack of a
standardized deﬁnition of ﬁtness. In both Canada and the
UK, it is recommended that discussions take place between
clinicians and patients and the centers of excellence for
EVAR be created. However, the decision to reimburse EVAR
in Ontario was based on a one-year prospective study in
which patients were stratiﬁed to the diﬀerent interventions
(OSR or EVAR) as a function of their baseline surgical risk
according to scoring algorithms [7]. In particular, in our
study, EVAR was not oﬀered to patients at a low risk of
surgical complications. Since the review by Jonk of cost-
eﬀectiveness of AAA repair and the publication of this trial-
based cost-eﬀectiveness study in high risk patients [8, 9],
recent studies have oﬀered mixed results when EVAR is
compared to OSR [10–15]. However, no studies have to
this point presented clinical, health-related quality of life
(HRQoL), and economic data based on risk classiﬁcation.
To better inform decision-making regarding the diﬀusion
of EVAR, this paper presents unpublished data on the one-
year clinical, HRQoL and economic outcomes associated
with OSR in low risk patients and how they compare with
EVAR and OSR in high risk patients. We also report 5-year
mortality data on EVAR patients.
2. Methods
2.1. Study Design and Participants. All patients requiring
elective repair of their AAA (AAA > 5.5cm) at LHSC,
Ontario, in 2003–2005 were invited to participate in a
p r o s p e c t i v eo b s e r v a t i o n a ls t u d yo fE V A Ra g a i n s tO S Rf o r
patients at a high or low surgical risk for perioperative
death and morbidity. Demographic, medical, HRQoL, and
resource utilization data was collected from participating
patients at baseline, discharge time from hospital, and at
one, three, six, nine, and twelve months postsurgery. The
details of the study design and methods have been previously
published but are brieﬂy presented below [8].
2.2. Treatment Algorithm. The method of AAA repair was
determined following institutional clinical criteria for endo-
vascular aneurysm surgery and through discussion with the
patient [3]. The eligibility of patients for surgical options
was evaluated based on the presence of comorbidities [16].
Surgical repair of AAAs in patients considered to be of
low surgical risk was completed with OSR. For patients
anatomically suitable for EVAR, the choice of EVAR or OSR
was presented as surgical options. High risk patients not
anatomically suitable for EVAR were treated using OSR. All
patients were oﬀered best medical treatment should they
not chose surgical options. Figure 1 presents the treatment
algorithm. In particular, all EVAR patients were at high
surgical risk.
2.3. Clinical Outcome Measures. Several measures of clin-
ical outcomes were used in this study including primary
technical success (PTS), intraoperative and postoperative
complications, thirty-day and 1-year mortality, as well as
overall survival. Five-year mortality rates and causes of death
were also presented for EVAR patients as these patients
are followed up annually. Three deﬁnitions had to be met
all together for primary technical success for EVAR: (1)
successful introduction and deployment of the device, (2)
absence of surgical conversion or mortality, and (3) absence
of type I or III endoleaks, or graft limb obstruction [17].
For OSR patients, PTS required the successful replacement
or bypass of the aneurysmal segment with a prosthetic graft
in the absence of mortality or graft thrombosis either during
surgery or during the initial 24-hour postoperative period
[17].
2.4. Health-Related Quality of Life. HRQoL was assessed
using two validated quality of life (QoL) instruments that
have been used in previous EVAR studies [18–26]. The Short
Form-36 Health Survey (SF-36), a generic quality of life
questionnaire [27], includes a multi-item scale that assesses
eight health domains: physical functioning, social func-
tioning, role-physical, bodily pain, general mental health,
role-emotional, vitality, and general health perceptions. A
score ranging from 0 to 100 can be generated for each
domain with higher scores indicating a better quality of
life. The European Quality of Life questionnaire (EQ-5D),
a preference-based questionnaire, consists of ﬁve questions
deﬁningﬁvehealthstatesintermsofmobility,self-care,usual
activities, pain/discomfort, and anxiety/depression. For each
of the ﬁve individual questions of the EQ-5D instrument,
three degrees of impairment are possible: no impairment,
some impairment, and extreme impairment. The individual
responses can be transformed into a utility score on a 0-
1 scale in which 0 corresponds to death and 1 to a perfect
health state) [28].
2.5.CostandCost-EﬀectivenessAnalyses. Aneconomicevalu-
ation of the trial data was conducted to compare the surgical
options in terms of one-year expected costs and life years.
To represent both payer and societal perspectives, resource
utilization (e.g., hospitalization, physician visits) and pro-
ductivity lost (e.g., days missed from work if employed) data
were prospectively collected. LHSC case costing data and
public sources were used to cost out the resource utilization
and productivity losses. For each treatment group, life-
years were determined and used as the primary eﬀectiveness
measure for the cost-eﬀectiveness analysis. In the absence of
dominance (e.g., EVAR more eﬀective and less costly than
OSR), the incremental cost per life-year gained of EVARInternational Journal of Vascular Medicine 3
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Figure 1: Treatment algorithm for elective repair.
compared to OSR was determined for low and high risk OSR
patients. All cost values in the paper are expressed in 2006
Canadian dollars (CAD).
2.6. Statistical Analyses. Continuous and discrete variables
were summarized using mean values (standard deviations)
and percentages, respectively. Statistical signiﬁcance was
conducted using Chi-square tests for categorical variables
and t-tests for continuous variables. Kaplan Meyer curves
were used to compare-treatment options and determine
life years over the one year period following the surgery.
In the economic analysis, one-year costs and eﬀects were
bootstrapped to express sampling uncertainty associated
with the trial data. The analyses were conducted for EVAR,
OSRamongpatientsatalowsurgicalrisk(OSRLR)andhigh
surgical risk (OSR HR).
3. Results
3.1. Patient Baseline Characteristics. Between August 11,
2003 and April 3, 2005, 140 patients were treated with
EVAR, 195 with OSR, and 7 with BMT. Of the patients
undergoing OSR, 52 patients were high risk and 143 low risk.
As shown in Table 1, EVAR- and OSR-HR treated patients
werecomparablewithrespecttotheirbaselinecharacteristics
with the exception of gender (P = .04) and the presence of
peripheral vascular disease (P<. 01). In contrast, the OSR
LR group was younger and had fewer baseline comorbidities
(Table 1).
3.2. Primary Technical Success. Among EVAR patients, the
PTS was 100%. All EVAR patients had successful introduc-
tionanddeployment oftheendograftsduring theprocedure,
and there were no surgical conversions, deaths, type I and
III endoleaks, or graft limb obstructions. Although almost
50% (47.9%) of type II endoleaks were reported on the
completion angiogram at the time of the initial procedure,
these type II endoleaks did not require an immediate cor-
rective procedure and the majority remained of no clinical
signiﬁcance over the study followup. PTS was assisted by
the completion of three unplanned endovascular procedures
in 2.1% of the EVAR patients. Four EVAR patients (2.9%)
had to undergo a planned endovascular procedure and
two others (1.4%) had additional procedures (e.g., inguinal
hernia repair). For OSR patients, PTS was also 100%.
3.3. Short and Mid-Term Mortality. The 30-day mortality
rate associated with EVAR (1 patient, 0.7%) was signiﬁcantly
lowerthantheOSRHRgroup(5patients,9.6%,P<. 01)and
similar to the OSR LR group (2 patients, 1.4%, P = 1.0). The
one postoperative death observed in the EVAR group was
attributedtocardiaccomplications.DeathsintheOSRgroup
were due to cardiac complications, pneumonia, respiratory
failure, or multiorgan failure. The one-year mortality rate
associated with EVAR was signiﬁcantly lower compared to
OSR HR patients (7.1% versus 17.3% resp.; P = .04) and
comparable to OSR LR patients (7.1% versus 4.2% resp.;
P = .28). The Kaplan Meier survival curves for the 3 patient
groups are presented in Figure 2. Out of a maximum of 1
in our one-year study, the life years associated with EVAR,
OSR LR, and OSR HR were calculated at 0.96 (SD: 0.15),
0.97 (SD: 0.15), and 0.85 (SD: 0.34), respectively. Out of
140 patients enrolled in EVAR, two were lost over the 5-
year followup period. With 50 deaths among the 138 EVAR
patients followed up for 5 years, the ﬁve-year mortality rate
was 36%. The main reasons of death were cancer (N = 10),
cardiac (N = 8), respiratory (N = 4), renal diseases (N = 4),
other (N = 3), and unknown (N = 21).
3.4. Other Perioperative and Postoperative Complications.
Complications at the time of surgery occurred in 2.7% of
all EVAR and OSR patients. No procedural graft thrombosis,
vein, or nerve injuries were observed. The percentage of
patients receiving blood transfusion at time of surgery was
statistically lower in EVAR patients (1%) than in OSR LR
(19.6%; P<. 01) and HR (46.2%; P<. 001) patients.
The need for additional procedures at time of surgery (e.g.,
renal artery revascularization and inferior mesenteric artery
reimplantation) was not statistically signiﬁcantly diﬀerent
between EVAR and OSR patients.
The 30-day postoperative complication rates were in
general lower in the EVAR patients compared to the OSR
HR patients and similar to OSR LR patients (Table 2).
Although 8.6% of EVAR patients had new type II endoleaks4 International Journal of Vascular Medicine
Table 1: Baseline characteristics of study participants.
Variable EVAR OSRhigh risk OSRlow risk
P Value EVAR
versus OSR high
risk
P Value EVAR
versus OSR high
risk
P ValueOSR
high risk versus
low risk
No. of patients, % 140 (100) 52 (26.6) 143 (73.4)
Age, yr (mean, SD) 75.6 ±7.87 4 .0 ±7.97 1 .7 ±7.9. 2 4 <.01 .06
min-max 59–93 54–91 52–87
Male gender, % 85.7 73.1 87.4 .04 0.68 .02
Smoking, % .07 <.01 .53
Current 22.8 34.6 40.6
Former 63.6 61.5 53.1
Never 13.6 3.9 6.3
Mean AAA size (cm) 6.2 ±0.96 .5 ±1.05 .9 ±1.0 .10 0.98 .10
SVS/ISCVS risk-factor
scores, % .97 <.01 <.01
I 34.3 34.6 83.9
II 65.7 65.4 16.1
ASA Grade, % .69 <.01 .02
I0 0 0
I I 1 . 404 . 2
III 32.1 33.3 50.3
IV 66.5 66.7 45.5
Leiden score (% of mortality) 6.9 ±4.37 .2 ±10.04 .1 ±2.8. 7 6 <.01 .04
Cardiovascular history, % 35.7 42.3 19.0 .40 <.01 <.01
Angina pectoris MI
<6 months 2.1 3.9 0.7 .61 .37 .17
>6 months 43.9 40.4 23.8 .66 <.01 .02
CHF, % 9.3 9.6 0 .94 <.01 <.01
Arrhythmia 25.0 21.2 7.8 .58 <0.01 <.01
Previous cardiac intervention
angioplasty/stent
GABG 11.4 7.7 7.0 .45 .20 1
Valve surgery 26.4 23.1 12.6 .64 <.01 .07
Hypertension 3.6 0 1.4 .33 .28 1
Stroke 81.3 75.0 74.1 .34 .15 .90
TIA 12.9 5.8 4.2 .16 <.01 .70
PVD 7.9 11.5 6.3 .41 .61 .23
10.1 30.0 8.6 <.01 .67 <.01
DM 19.3 19.2 11.9 .99 .09 .19
Renal disease, % 1.4 0 0.7 1 1 1
Pulmonary disease, %
COPD, % 35.7 41.2 20.4 .49 <.01 <.01
Emphysema, % 25.0 17.3 8.1 .26 <.01 .11
Asthma, % 2.9 7.7 4.9 .22 .38 .49
Other, %
Previous abdominal
surgery 45.3 34.6 28.7 .18 <.01 .48
Hostile abdomen 2.2 3.9 0.0 .61 .12 .07
AAA: Abdominal aortic aneurysm; ASA: American Society of Anesthesiologist; CHF: congestive heart failure; CABG: coronary artery bypass grafting; COPD:
chronic pulmonary disease; EVAR: endovascular aneurysm repair; MI: myocardial infarction; OSR: open surgical repair; SD: standard deviation; SVS/ISVS:
Society for Vascular Surgery/International Society for Cardiovascular Surgery.International Journal of Vascular Medicine 5
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Figure 2: Kaplan Meier Survival Plots for EVAR, OSR HR, and LR
patients up to 12 Months of Followup Kaplan Meyer.
within one year, they did not require any reintervention nor
were there any cases of aneurysm rupture, graft migration,
integrity problems, or obstruction of the endografts. One-
year vascular reoperation rates between treatment groups
were not statistically diﬀerent (i.e., 0.7% for EVAR, 2.1% for
OSR LR, and 4.4% for OSR HR).
3.5. Health-Related Quality of Life. No statistical diﬀerences
were observed in the baseline values of the eight dimensions
of the SF-36 between the treatment groups (Figure 3). Five-
dimensionscores(bodilypain,socialfunctioning,rolephysi-
cian, role emotional, and physical functioning) dropped
following the operation before returning to preoperative
levels after 3 months for OSR LR and HR patients. In
contrast, for EVAR patients, the scores associated with four
of these ﬁve domains returned to the preoperative levels
after 6 months and after 12 months for the ﬁfth domain
(role physical). At one year, EVAR patients had statistically
lower scores compared to OSR HR or OSR LR patients for
these ﬁve dimensions of the SF-36. No major changes were
observed over time and between treatments for the three
other domains of the SF-36 (general health, mental health,
and vitality) (Figure 4).
Similar to the pattern observed with the SF-36 data,
patients’ utilities decreased following the surgery and
increased over time thereafter (Figure 4). The utility scores
at 1 year were higher than the preoperative values for all
OSR patients. EVAR patients returned to their perioperative
levels. While the EQ-5D utility scoreswere similar at baseline
between the three groups, the 12-month utility scores were
lower for EVAR patients at 0.76 (SD: 0.26) compared to 0.89
(SD: 0.12) for OSR LR (P<. 001) and 0.93 (SD: 0.12) for
O S RL R( P = .015). Similar to the SF-36 results, the 1-year
scores were not diﬀerent between OSR patients (i.e., LR and
HR groups).
3.6. Costs and Cost Eﬀectiveness. From a resource uti-
lization point of view, EVAR required less procedural
time (162.4 minutes ± 46.5) than OSR in LR patients
(181 minutes ± 52.2) and in HR patients (195.8 minutes ±
64.8) (P<. 01 for both comparisons). In our study, 95%
of all EVAR patients received general anesthesia while the
majority of OSR patients received a general anesthesia with
epidural (67.3% for OSR HR and 76.9% for OSR LR).
Compared to OSR, EVAR patients spent less time in the
hospital and required fewer admissions to the intensive care
unit (ICU) (Table 3). Despite the additional cost of the
graft (e.g., approximately $10,000), the mean initial costs
of hospitalization were similar between the EVAR and OSR
HR groups ($28,139 versus $31,181, P = .28 resp.). Costs
of hospitalizations associated with OSR LR patients were
statistically signiﬁcantly less at $15,494 versus EVAR, P<
.05 (Table 3).
As the use of healthcare resources in the year following
the operation was higher in EVAR patients, the average 1-
year medical cost of followup was signiﬁcantly higher for
EVAR patients ($5,172) than OSR HR patients ($2,171) or
OSR LR patients ($1,890) (Table 3). No statistical diﬀerences
were observed in terms of indirect costs between the three
treatment groups (Table 3). In total, the average 1-year
cost of EVAR was $34,146 per patient, which compared to
$34,170 per OSR HR patient and $19,163 per OSR LR group.
The costs associated with OSR among LR patients were
statistically lower compared to the other two groups (P<. 05
for both comparisons).
Point estimates indicated that EVAR was less costly
($−24) and oﬀered additional beneﬁts (i.e., 0.12 life-year
gained) than OSR in high risk patients. However, EVAR
was dominated by OSR in low risk patients (e.g., OSR less
costlyandmoreeﬀectivethanEVARinhighriskpopulation).
These results held true even when the uncertainty was
taken into account as shown in Figure 5 which presents the
cost-eﬀectiveness acceptability curves used to represent the
uncertainty. The way to interpret these curves is to consider
a threshold that decision makers might be willing to pay
for a unit of eﬀect (i.e., willingness to pay per one life-year
gained) along the horizontal axis and read along the vertical
axis the probability that the treatment is cost-eﬀective after
accounting for uncertainty. For example, if society is willing
to pay an extra $50,000 and $100,000 to save one extra year
oflife,theprobabilityofEVARbeingcost-eﬀectivecompared
to OSR in high risk patients was 0.76 and 0.90, respectively,
while these probabilities were almost 0 when EVAR was
compared to OSR in low risk patients.
4. Discussion
The results of this 1-year study showed that at the current
price of the endografts (approximately $10,000 at time of
study), EVAR in high risk patients may be cost-eﬀective
compared to OSR in high risk patients but not in low risk
patients. Speciﬁcally, a signiﬁcant reduction in the 30-day
and 1-year mortality rates was observed in favor of EVAR for
high risk patients. However, when EVAR in high risk patients
was compared to OSR in low risk patients, these mortality
diﬀerences were not signiﬁcant. In terms of costs, the 1-
year cost of EVAR was similar to OSR in high risk patients6 International Journal of Vascular Medicine
Table 2: Postoperative complications (30 days or to discharge).
Postoperative
complications
EVAR
(n = 140)
OSR High Risk
(n = 52)
OSR Low Risk
(n = 143)
EVAR versus
OSR High Risk
EVAR versus
OSRLow Risk
OSR High
versus Low Risk
Death 1 (0.7%) 5 (9.6%) 2 (1.4%) P<. 01 P = 1.00 P = .02
MI 6 (4.3%) 5 (9.6%) 7 (4.9%) P = .17 P = .80 P = .31
CHF/Pulmonary edema 5 (3.4%) 9 (17.3%) 16 (11.1%) P<. 01 P = .49 P = .26
Arrythmia 5 (3.6%) 5 (9.6%) 8 (5.6%) P = .14 P = .40 P = .34
Stroke 1 (0.7%) 0 0 P = 1.00 P = 1.00 P = 1.00
Renal failure 5 (3.6%) 6 (11.5%) 5 (3.5%) P = .07 P = 1.00 P = .07
Pneumonia 0 4 (7.7%) 7 (4.9%) P<. 01 P = .02 P = .04
Sepsis 0 3 (5.8%) 1 (0.7%) P = .02 P = 1.00 P = .06
Paralytic ileus 0 4 (7.7%) 6 (4.2%) P<. 01 P = .03 P = .46
Wound
Infection/lymphocele 1 (0.7%) 1 (1.9%) 0 P = .27 P = .50 P = .27
Graft occlusion 0 0 0 P = 1.00 P = 1.00 P = 1.00
Blood transfusion 11 (7.9%) 11 (21.2%) 8 (5.6%) P = .02 P = .45 P<. 01
Vascular reoperation 1 (0.7%) 1(4.4%) 3 (2.1%) P = .50 P = .62 P = 1.0
Arterial embolus 1 (0.7%) 0 1 (0.7%) P = 1.00 P = 1.00 P = 1.0
Urinary tract infection 0 1 (1.9%) 1 (0.7%) P = .27 P = 1.00 P = .46
GI bleed 0 0 2 (1.4%) P = 1.00 P = .50 P = 1.00
Other surgery 1 (0.7%) 3 (5.77%) 1 (0.7%) P = .06 P = 1.00 P = .66
Table 3: One-year resource utilization and cost.
Variable EVAR OSR,
High risk
OSR,
Low risk
DiﬀerenceEVAR
versus OSR
High risk
Diﬀerence EVAR
versus OSR
Low risk
Diﬀerence OSR
High—versus
Low risk
No. of patients 140 52 143
Initial hospitalization
Duration of stay in
hospital, day (mean, SD) 7.7 (5.8) 16.1 (16.0) 9.4 (5.2) −8.43 −1.66 6.77
Frequency of attendance in
ICU, % 5 (3.6) 16 (30.8) 9 (6.3) −27.20 −2.70 24.5
Mean duration of stay in
ICU (SD) 0.23 (1.71) 3.21 (8.25) 0.27 (1.4) −2.98 −0.04 2.94
Subtotal costs $28,139 $31,181 $15,494 −$3,042 $12,645∗ −$15,687∗
Followup, mean number of:
Hospital admissions 0.36 0.13 0.20 0.23 0.16 −0.07
ER Visits 0.93 0.31 0.51 0.62 0.42 −0.20
GP Visits 6.37 5.48 5.84 0.89 0.54 −0.35
Specialist visits 4.19 1.65 1.65 2.54 1.85 −0.69
Vascular surgeon visits 2.74 0.96 0.96 1.78 1.47 −0.31
CT scans 2.61 0.10 0.10 2.51 2.55 −0.04
Subtotal costs $5,172 $2,171 $1,890 $3,010∗ $3,282∗ $272
Followup, productivity
Mean paid days taken oﬀ
work 3.91 3.23 8.90 0.68 −4.99 −5.67
Mean hours of care
provided by others 18.6 23.0 35.07 −4.40 −16.47 −12.07
Subtotal costs $835 $818 $1,779 $17 −$944 −$961
Total costs 34,146 $34,170 $19,163 −$24 $14,983∗ −$15,007∗
∗: Indicate signiﬁcance at 5% level.International Journal of Vascular Medicine 7
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Figure 5: Cost-eﬀectiveness acceptability curves ($/LYG).
despite the additional cost of the graft. In comparison,
treating low risk patients with OSR was estimated to save
almost $15,000 per year for similar mortality beneﬁts. In
addition, the study consistently showed that at 1-year OSR
patients, independent of their surgical risk, had a better
HRQoL than EVAR patients. This study also found that
scoring algorithms could be used to identify patients who
would beneﬁt the most from EVAR (e.g., patients at a high
risk of perioperative morbidity and death) or OSR (e.g., low
risk patients). This was conﬁrmed in our study as EVAR and
OSR high risk patients were similar with respect to baseline
variables (e.g., age, AAA size, Leiden mortality rates) despite
the nonrandomized nature of the trial. In comparison, low
risk patients undergoing OSR were younger and had fewer
comorbidities than high risk patients treated with EVAR and
OSR.
Our study is unique in several ways. As opposed to the
randomized trials EVAR, DREAM, ACE, and OVER which
enrolledpatientswithalow tomoderatesurgicalrisk [19,24,
29,30],allEVARpatientswerehighriskpatientsinourstudy.
In comparison approximately 7% of EVAR and OSR patients
enrolled in the OVER trial were at high surgical risk, while
more than half of the patients were at low risk. Similarly
many nonrandomized studies have included a mixed patient
risk populations [31]. As such it is diﬃcult to compare
our results with all previously completed randomized or
nonrandomized studies. In contrast to other studies, we
also present outcome data on low and high risk patients
treated with OSR thus providing previously unavailable
information. Finally we collected health-related quality of
life and resource utilization data to perform an economic
evaluation of the trial, which was used to inform policy
making in Ontario. As such our data are very relevant from a
clinical practice point of view as it is aligned with the current
Canadian guidelines for the management of AAAs (e.g.,
EVAR not recommended in low risk patients) and funding
recommendations in Ontario (EVAR not reimbursed for low
risk patients).
It is also diﬃcult to compare our cost-eﬀectiveness
ﬁndings with previous studies. With the exception of a few
studies, EVAR has not been found cost-eﬀective compared to
OSR which may be due to the fact that many randomized
or observational studies do not explicitly separate out OSR
patients based on presurgical risk. For example, our own
10-year decision analytic model populated with clinical data
derived from a systematic literature and cost data from the
ﬁeld evaluation indicated that at an incremental cost of
more than $400,000 per life year gained, EVAR was not
cost-eﬀective compared to OSR in Canada [12]. In this
paper, the 30-day mortality rate derived from a systematic
literature review was 1.5% for EVAR (compared to 0.7%
in our study) and 4% for OSR (compared to 1.4% in low
risk patients and 9.6% in high risk patients receiving OSR).
When the trial 30-day mortality rates observed in high risk
patients who underwent EVAR and OSR were used in the
model decision model (i.e., a diﬀerence of 8.2% in 30-day
mortality versus 2.5% in the original publication), EVAR
became cost-eﬀective at a cost-eﬀectiveness ratio of less than
$50,000 per LYG over a 10-year time horizon. Recent model-
based cost-eﬀectiveness analyses have also shown that EVAR
may be cost-eﬀective in high risk patients. For example,
the model conducted by NICE to inform the use of EVAR
in the UK concluded that “the ICER for patients of good
ﬁtness suggested that EVAR was not what would be usually
agreed as a good use of NHS resources in these patients”
[6, Section 4.3.14, page 27]. However, in the absence of
“nationally agreed deﬁnitions of ﬁtness for surgery”, the
Committee felt that it would be inappropriate to exclude a
speciﬁc group of patients suitable for surgery. NICE however
recognized that the decision between EVAR and OSR should
be individualized based on AAA size, patients’ morphology
and ﬁtness to OSR [5]. In our study, low risk patients
were treated with OSR and high risk patients anatomicallyInternational Journal of Vascular Medicine 9
suitable for EVAR were oﬀered both surgical options. Results
indicated that OSR was the most attractive option for low
risk patients from a health economic standpoint. Although
EVAR is a clinically acceptable and eﬀective procedure for
low risk patients, currently it is more expensive. Finally, our
5-year mortality rate of EVAR at 36% was comparable to
6-year mortality rate of 31% that was reported by DREAM
trial [32]. Since OSR patients did not require similar long-
term followup, we were not able to provide any information
regarding their 5-year mortality.
Severallimitationswereassociatedwithourstudyinclud-
ing its nonrandomized nature. However, high risk patients
treated with EVAR and OSR were similar in terms of baseline
characteristics allowing direct comparisons between these
two populations of HR patients. Although OSR patients at
a lower surgical risk were not comparable with EVAR or
OSR HR patients, we did not adjust the results comparing
EVAR HR patients and OSR in LR patients, which may be
a limitation of the analyses comparing EVAR versus OSR in
LR patients. However, it is expected that OSR patients at a
lower surgical risk will spend less time in the hospital that
their high risk counterparts. It was therefore not surprising
that the diﬀerence of $15,000 observed in the 1-year costs
between OSR HR and LR patients was mostly due to the
higher costs of hospitalization observed in the high risk
group. Interestingly and despite the observational nature of
our data, the three treatment groups were similar in terms of
HRQoLpriortothesurgery(e.g.,SF-36domainsandEQ-5D
utilities). Another limitation associated with this study was
related to the limited number of OSR high risk patients (N =
52). However, bootstrap techniques were used to deal with
the uncertainty associated with the trial data, and CEACs
were used to represent this uncertainty. This study was also
conducted in a single hospital in Ontario which may limit
the generalizability of the results. It is also important to note
that LHSC, which has an established endovascular program,
is a primary center of referral and may not reﬂect the mix
of patients seen in other institutions. Finally all enrolled
patients had an AAA > 5.5cm and as such the results cannot
be generalized for smaller aneurysms.
Despite these limitations, this study provides new and
currently unavailable information on the comparative costs
and outcomes associated with treatment options for patients
with an AAA > 5.5cm. Our results do not support reim-
bursement of EVAR for low risk patients at the current price
of the endografts despite a similar clinical eﬀectiveness. In
light of these ﬁndings and to better inform decision making
around EVAR, future trials of EVAR should use scoring
algorithms to allow stratiﬁed analyses by surgical risk.
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